EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cardiovascular-kidney-metabolic syndrome – An integrative review

Katiana Simões Kittelson, Arquimedes Gasparotto Junior, Natasha Fillmore, Roberto da Silva Gomes

Progress in Cardiovascular Diseases · 2024-11 · 87 · 26-36

DOI: 10.1016/j.pcad.2024.10.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2024-11. Verfasst von Katiana Simões Kittelson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cardiovascular Pharmacology (LaFaC), Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados, MS, Brazil; De…. Hauptthemen laut MEDLINE: Metabolic Syndrome, Biomarkers. Die Arbeit wurde bisher 116-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The American Heart Association recently defined the complex interactions among the cardiovascular, renal, and metabolic systems as CKM syndrome. To promote better patient outcomes, having a more profound understanding of CKM pathophysiology and pursuing holistic preventative and therapy strategies is critical. Despite many gaps in understanding CKM syndrome, this study attempts to elucidate two of these gaps: the new emerging biomarkers for screening and the role of inflammation in its pathophysiology. For this review, an extensive search for specific terms was conducted in the following databases: PubMed, Scopus, Web of Science, and Google Scholar. Studies were first assessed by title, abstract, keywords, and selected for portfolio according to eligibility criteria, which led to 38 studies. They provided background information about CKM syndrome; data suggested that serum uric acid, leptin, aldosterone, bilirubin, soluble neprilysin, lipocalin-type-prostaglandin-D-synthase, and endocan could be valuable biomarkers for CKM screening; and finally, the inflammation role in CKM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeBiomarkersHumansCardio-Renal SyndromePrognosisInflammation MediatorsRisk Assessment

Stichwörter der Autor:innen

CaReMe risk factorsCardio-renal-metabolic syndromeNoncommunicable diseases

Substanzen

BiomarkersInflammation Mediators

Autor:innen und Institutionen

  • Laboratory of Cardiovascular Pharmacology (LaFaC), Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados, MS, Brazil; Department of Pharmaceutical Sciences, College of Health and Human Scien…
  • Laboratory of Cardiovascular Pharmacology (LaFaC), Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados, MS, Brazil.
  • Department of Pharmaceutical Sciences, College of Health and Human Sciences, North Dakota State University, Fargo, ND, United States.
  • Department of Pharmaceutical Sciences, College of Health and Human Sciences, North Dakota State University, Fargo, ND, United States. Electronic address: roberto.gomes@ndsu.edu.

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Kittelson, K. S., Junior, A. G., Fillmore, N., & da Silva Gomes, R. (2024). Cardiovascular-kidney-metabolic syndrome – An integrative review. Progress in Cardiovascular Diseases, 87, 26-36. https://doi.org/10.1016/j.pcad.2024.10.012

Vancouver

Kittelson KS, Junior AG, Fillmore N, da Silva Gomes R. Cardiovascular-kidney-metabolic syndrome – An integrative review. Progress in Cardiovascular Diseases. 2024;87:26-36. doi:10.1016/j.pcad.2024.10.012

BibTeX
@article{Kittelson2024,
  author = {Kittelson, Katiana Simões and Junior, Arquimedes Gasparotto and Fillmore, Natasha and da Silva Gomes, Roberto},
  title = {Cardiovascular-kidney-metabolic syndrome – An integrative review},
  journal = {Progress in Cardiovascular Diseases},
  year = {2024},
  volume = {87},
  pages = {26--36},
  doi = {10.1016/j.pcad.2024.10.012}
}
Kostenlos starten →